巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Rhythm Pharmaceuticals

RYTM
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Rhythm Pharmaceuticals - 延遲價格・最後更新於 26/01 6:38
最高位
7.980
最低位
7.470
開市價
--
前收市價
7.770
成交量(千)
10.92
成交額(百萬)
0.78
買入
7.770
賣出
7.870
每手股數
--
市值(百萬)
394.10
市盈率
--
息率
--
差價
--
52週高低
43.260 - 6.950
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Rhythm Pharmaceuticals
證券代碼
RYTM.US
所屬板塊
Biotechnology
公司業務
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.
發行量
50201758
公司總部
222 Berkeley Street, 12th Floor
公司網址
http://www.rhythmtx.com
公司電郵
dconnolly@rhythmtx.com
公司電話
+1 857 264-4280
暫無內容

關於

Rhythm Pharmaceuticals(RYTM.US)所屬的行業板塊為Biotechnology。
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.
詳細公司背景可參考: http://www.rhythmtx.com